Free Trial
NASDAQ:CDNA

CareDx (CDNA) Stock Price, News & Analysis

CareDx logo
$19.30 +1.86 (+10.67%)
As of 06/4/2025 04:00 PM Eastern

About CareDx Stock (NASDAQ:CDNA)

Key Stats

Today's Range
$18.12
$19.75
50-Day Range
$14.18
$19.30
52-Week Range
$13.18
$34.84
Volume
1.70 million shs
Average Volume
902,005 shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.33
Consensus Rating
Moderate Buy

Company Overview

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CareDx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

CDNA MarketRank™: 

CareDx scored higher than 72% of companies evaluated by MarketBeat, and ranked 297th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CareDx has only been the subject of 3 research reports in the past 90 days.

  • Read more about CareDx's stock forecast and price target.
  • Earnings Growth

    Earnings for CareDx are expected to grow in the coming year, from ($0.90) to ($0.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CareDx is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CareDx is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CareDx has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CareDx's valuation and earnings.
  • Percentage of Shares Shorted

    12.62% of the float of CareDx has been sold short.
  • Short Interest Ratio / Days to Cover

    CareDx has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in CareDx has recently increased by 7.01%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CareDx does not currently pay a dividend.

  • Dividend Growth

    CareDx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.62% of the float of CareDx has been sold short.
  • Short Interest Ratio / Days to Cover

    CareDx has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in CareDx has recently increased by 7.01%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CareDx has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for CareDx this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,458,009.00 in company stock.

  • Percentage Held by Insiders

    Only 4.90% of the stock of CareDx is held by insiders.

  • Read more about CareDx's insider trading history.
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Stock News Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
CareDx Announces Repurchase of 5% of Outstanding Shares
CareDx Inc.
CareDx, Inc (NASDAQ:CDNA) Director Sells $523,500.00 in Stock
See More Headlines

CDNA Stock Analysis - Frequently Asked Questions

CareDx's stock was trading at $21.41 at the beginning of the year. Since then, CDNA shares have decreased by 9.9% and is now trading at $19.30.
View the best growth stocks for 2025 here
.

CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings data on Wednesday, April, 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The business's revenue for the quarter was up 17.6% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of CareDx include Vanguard Group Inc. (8.68%), Invesco Ltd. (4.79%), ARK Investment Management LLC (4.22%) and Fred Alger Management LLC (2.58%). Insiders that own company stock include Reginald Seeto, Abhishek Jain, Peter Maag, Alexander L Johnson, William A Hagstrom, Christine Cournoyer and Grace Colon.
View institutional ownership trends
.

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
4/30/2025
Today
6/05/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:CDNA
Employees
740
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.33
High Stock Price Target
$40.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+57.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$190.28 million
Pretax Margin
-45.80%

Debt

Sales & Book Value

Annual Sales
$346.42 million
Price / Cash Flow
N/A
Book Value
$4.83 per share
Price / Book
4.00

Miscellaneous

Free Float
51,006,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
2.27

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:CDNA) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners